Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
(S)-PHA-533533 is an inhibitor of cyclin-dependent kinase 2 (Cdk2)/cyclin A, Cdk2/cyclin E, Cdk5/p25, and Cdk1/cyclin B complexes and glycogen synthase kinase 3β (GSK3β; IC50s = 37, 55, 65, 208, and 732 nM, respectively, in cell-free assays).1 It selectively inhibits these complexes and GSK3β over the Cdk4/cyclin D1 complex and a panel of 29 other kinases at 10 µM. (S)-PHA-533533 inhibits the growth of A2780 ovarian, HT-29 human colon, and HCT116 colorectal cancer cells (IC50s = 744, 639, and 1,354 nM, respectively) and induces cell cycle arrest at the G0/G1 phase in HT-29 cells. It reduces tumor growth in an A2780 mouse xenograft model when administered at a dose of 7.5 mg/kg. (S)-PHA-533533 also restores the expression of paternal UBE3A mRNA in a mouse model of Angelman syndrome.2
WARNING This product is not for human or veterinary use.
1. 3-
2. Ube3a unsilencer for the potential treatment of Angelman syndrome. Nat. Commun. 15(1), 5558 (2024).